Comparing weight-loss surgeries for diabetes remission in people with severe obesity
Compares 3 weight-loss operations for type 2 diabetes remission in adults with severe obesity.
Plain-language title generated from the registry record
Registry title: Diabetes Remission and Hypoabsorptive Bariatric Surgery
Key facts
- Where
- L'Hospitalet de Llobregat, SpainSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT06043245, who can take part
Where in Spain
- Hospital Universitari de BellvitgeL'Hospitalet de Llobregat, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hospital Universitari de Bellvitge
- Trial code
- NCT06043245
- Record updated
- 21 September 2023
- Original description
Bariatric surgery is the most effective treatment to achieve type 2 Diabetes Mellitus (DM) remission in patients with severe obesity. However, there is little evidence of the effectiveness and pathophysiological mechanisms involved in metabolic improvement after hypoabsortive tecniques such as duodenal switch (DS), single anastomosis duodenal switch (SADI-S) or minigastric bypass (MGB). We have designed a randomized study to compare type 2 diabetes remission after the 3 bariatric procedures in patients with severe obesity (BMI > 45kg/m2) and to study the implication of gastrointestinal hormones, bile acids and gut microbiota in metabolic improvement in each procedure.Read full original descriptionShow less
Prognostic Factors and Predictors of Diabetes Remission in Hypoabsorptive Bariatric Surgery Techniques. Randomized Comparative Study Between Duodenal Switch, Single-Anastomosis Duodenal Switch (SADI-S) and Mini-Gastric Bypass
Bariatric surgery is the most effective treatment to achieve type 2 Diabetes Mellitus (DM) remission in patients with severe obesity. However, there is little evidence of the effectiveness and pathophysiological mechanisms involved in metabolic improvement after hypoabsortive tecniques such as duodenal switch (DS), single anastomosis duodenal switch (SADI-S) or minigastric bypass (MGB). We have designed a randomized study to compare type 2 diabetes remission after the 3 bariatric procedures in patients with severe obesity (BMI > 45kg/m2) and to study the implication of gastrointestinal hormones, bile acids and gut microbiota in metabolic improvement in each procedure.
Inclusion: BMI>45 kg/m2; T2D on treatment with hypoglycemic agents alone, insulin or both.
Exclusion: Positivity for GAD auto-antibodies; Previous bariatric surgery; Type 1 diabetes; Secondary forms of diabetes; Severe liver disease; Acute metabolic complications in the last 6 months; Renal dysfunction; Patients under anticoagulant treatment; Congenital or acquired abnormalities of the digestive tract; Pregnancy; Nursing or desired pregnancy in the 12 months following inclusion; Corticoid use by oral or intravenous route for more than 14 consecutive days in the last three months.